Loss-of-function mutations in BRIP1 resulting in reduced helicase activity and/or altered BRIP1-BRCA1 interaction [17] have been linked to an increased risk for breast [17, 19, 24], ovarian [19, 25–27], prostate [28, 29], and pancreatic cancer, [30, 31]. This evidence concerns the gene BRIP1 and pancreatic neoplasm.